Opioid constipation stops responding to laxatives because the stool is not the problem. Every opioid, including methadone and buprenorphine, reaches a receptor built into the bowel wall. The gut never builds tolerance to that effect. Laxatives work on the stool. The treatment that works aims at the receptor, and at the dose driving it.
Here is the part nobody says out loud in a recovery program. A survey looked at 322 people taking daily opioids for chronic pain plus a laxative. A third had missed, cut or stopped an opioid dose to make it easier to have a bowel movement. They were running their own taper, with no one watching, just to use the bathroom. Say that medicine is the methadone or buprenorphine holding your recovery steady. Then that is not a bathroom problem. It is a treatment problem.
The argument comes from Chapter 21, “The Narcotic Bowel,” of The Angry Gut. Dr. Gurpreet Singh Padda, MD, MBA, MHP, wrote the book with Ami Michelle Grimes. It was released September 28, 2026. The chapter’s free technical supplement holds the full evidence.
Why do opioids stop the bowel from moving?
In the brain, an opioid aims at the mu-opioid receptor. That same receptor is wired through the gut. In human tissue it sits on the nerve cells in both layers of the bowel wall. It also sits on immune cells just under the lining. Animal work puts it on both halves of the reflex that pushes food forward. Your gut already runs on its own small opioid signal. A daily dose arrives as a flood. The receptor does not ask whether the drug came from a pain prescription, a clinic dose or the street.
I was taught that opioids simply switch the bowel off. I told patients exactly that for years. The recordings in people say otherwise. Morphine drives the small bowel into squeezes that fire out of order and move nothing forward. Meanwhile, the valves downstream clamp shut. The engines are revving and the road is closed. In a Mayo Clinic trial, 72 healthy adults who had never taken opioids got codeine for just three days. It slowed the stomach, the filling of the colon and the movement through the colon.
Why don’t laxatives work for opioid constipation?
Your brain adapts to an opioid. That is tolerance. It is why a dose that once quieted pain or withdrawal stops doing as much. The bowel does not adapt. A 2026 review of American, European and Japanese guidelines says it plainly. Opioid constipation persists, is not tied to tolerance and needs long-term care. The same review says standard laxatives often fall short. They treat secondary symptoms instead of the receptor-driven cause.
The survey of 322 patients shows what that looks like from the inside. Every one of them was already taking a laxative. Even so, 81% were constipated. And 45% had fewer than three bowel movements a week. Most symptoms showed up four or more days out of seven. People quit a laxative because it keeps failing, not because they are careless.
Lubiprostone is a newer drug that pulls water into the stool. It did better than placebo in a trial of adults with chronic non-cancer pain. Of those on it, 27.1% responded, against 18.9% on placebo. Quality of life did not change in any measurable way. If you take methadone, notice who was studied. The trial enrolled people on non-methadone opioids only. A symptom managed forever sells better than a cause fixed once. That is milking the cow rather than curing the cow.
What actually treats opioid constipation?
First, the filing. Constipation on an opioid earns a line on the problem list, beside the diagnosis. It does not belong in the side-effect column with a stool softener next to it. A problem gets a plan; a side effect gets tolerated.
Second, the receptor. One class of drugs blocks the receptor in the bowel but leaves the brain effects alone. Doctors call them peripherally acting mu-opioid receptor antagonists. Two identical randomized trials tested naldemedine in adults with chronic non-cancer pain on a stable opioid dose. In the first trial, 47.6% of patients responded, against 34.6% on placebo. In the second, 52.5% responded, against 33.6%. The bar was high. Patients needed three or more bowel movements a week without help, for at least 9 of 12 weeks. Overall side effects matched placebo. Gut side effects ran about twice as often, which you expect when a stalled bowel restarts. One network analysis pooled 27 randomized trials and 9,149 patients. It ranked oral naloxone and naldemedine as the most effective options. Japan’s 2023 guidelines go further. They back naldemedine as a primary treatment, started early rather than after laxatives fail.
For someone on buprenorphine or methadone, the design matters. These blockers are built to act in the gut. Your recovery medicine does its work in the brain. Whether one fits your full medication list is a decision made in person. It takes a physician who sees the whole list.
Third, the terrain. One outpatient addiction-treatment study looked at gut bacteria. The 5 people using opioid agonists, such as heroin or prescription opioids, had less diverse gut bacteria. They had less Roseburia, which makes the butyrate that feeds the cells sealing the gut wall. They also had less Bilophila, which handles bile acids. The 4 people on buprenorphine-naloxone showed no such gap compared with people using neither. Those groups are tiny, and it was a single snapshot. But it is the pattern you would expect if the receptor is the switch.
When is stomach pain on opioids a warning sign?
Narcotic bowel syndrome is belly pain that grows worse even as the opioid dose stays level or rises. About 6% of people on narcotics long term develop it. It is a nervous-system problem, separate from constipation, though the two often travel together. More drug feeds it. It calls for a physician who treats pain and addiction as one problem.
The cost runs past the gut. People plan their day around a bathroom. They skip meals before leaving the house, and slowly stop leaving it. Isolation is one of the forces that drives both chronic pain and addiction. A stalled bowel quietly builds it.
What should you bring to your next appointment?
Do not change a dose on your own. Bring three things instead.
- A timeline. When did your dose last change, and what did your bowel do in the eight weeks after? Put those dates side by side.
- A count. How many days a week are you straining? How many days are you taking something for it? “Only when it gets bad” is an answer worth saying out loud.
- The right question. Not “can I have something for constipation.” Ask whether this is a side effect on your list or a problem on your problem list. Then ask whether a drug that blocks the receptor in your bowel fits you.
Then answer one more for yourself. How many times last month did you skip or shrink a dose to get a bowel movement? Tell the person who prescribes your medicine. Addictionology Center treats opioid addiction in person in St. Louis, with pain and the gut on the same chart. For the pain side of the same problem, read when the opioid dose falls because the pain did.
Frequently asked questions
Can buprenorphine or methadone cause constipation?
Yes. Both act on the mu-opioid receptor, which lines the bowel wall as well as the brain. The bowel does not build tolerance to that effect the way the brain does. That is why constipation can last as long as you take the medicine. And that is why it deserves a plan rather than a shrug.
Why is my stool softener not working on opioids?
A softener works on the stool. The stall comes from opioid receptors in the bowel wall. A survey looked at 322 people on daily opioids who already took laxatives. Of them, 81% were still constipated. Drugs that block the receptor in the gut target the cause instead.
Is it safe to skip a dose to have a bowel movement?
Skipping or shrinking doses on your own is a taper with no one watching. A third of surveyed patients on daily opioids and laxatives had done it. If you are on methadone or buprenorphine for recovery, tell your prescriber instead. The bowel can be treated directly.
Related reading
Methadone Reduces Treatment Dropout More Than Buprenorphine · Mindfulness Cuts Opioid Treatment Dropout and Relapse
Sources
- Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Medicine. 2009;10(1):35–42. PMID 18721170 · DOI 10.1111/j.1526-4637.2008.00495.x.
- Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterology and Motility. 2004;16(Suppl 2):3–16. PMID 15357847 · DOI 10.1111/j.1743-3150.2004.00553.x.
- Lewis TD. Morphine and gastroduodenal motility. Digestive Diseases and Sciences. 1999;44(11):2178–2186. PMID 10573360 · DOI 10.1023/a:1026684132254.
- Halawi H, Vijayvargiya P, Busciglio I, et al.. Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: a randomized, controlled trial. Neurogastroenterology and Motility. 2018;30(5):e13298. PMID 29405492 · DOI 10.1111/nmo.13298.
- Manabe N, Ihara E, Yomiya K, et al.. Current strategies and future perspectives in the management of opioid-induced constipation: a review of international and Japanese guidelines. Neurogastroenterology and Motility. 2026;38(5):e70343. PMID 42093290 · DOI 10.1111/nmo.70343.
- Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. The American Journal of Gastroenterology. 2015;110(5):725–732. PMID 25916220 · DOI 10.1038/ajg.2015.106.
- Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. The Lancet Gastroenterology & Hepatology. 2017;2(8):555–564. PMID 28576452 · DOI 10.1016/S2468-1253(17)30105-X.
- Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut. 2019;68(3):434–444. PMID 29730600 · DOI 10.1136/gutjnl-2018-316001.
- Gicquelais RE, Bohnert ASB, Thomas L, Foxman B. Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. Scientific Reports. 2020;10(1):19471. PMID 33173098 · DOI 10.1038/s41598-020-76570-9.
- Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. American Journal of Gastroenterology Supplements. 2014;2(1):22–30. PMID 25207609 · DOI 10.1038/ajgsup.2014.6.
- Padda GS, Grimes AM. The Angry Gut: The First Brain: Older Than Thought, and Still in Charge. Nectar Media Group; 2026. Chapter 21, “The Narcotic Bowel.” ISBN 978-0-9832058-2-1. Chapter 21 technical supplement.
Bibliographic records in this article were retrieved from PubMed. Every journal reference links to its PubMed record and DOI.